DAFNA Capital Management »

Stoke Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Stoke Therapeutics (STOK) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Stoke Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Stoke Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Stoke Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $2.0M 145k 13.50

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Cytokinetics Com New (CYTK)
Ideaya Biosciences (IDYA)
Merus N V (MRUS)
Revolution Medicines (RVMD)
Viking Therapeutics (VKTX)
Syndax Pharmaceuticals (SNDX)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ascendis Pharma A/s Sponsored Adr (ASND)
Xenon Pharmaceuticals (XENE)
Day One Biopharmaceuticals I (DAWN)
Blueprint Medicines (BPMC)
Neurocrine Biosciences (NBIX)
Kalvista Pharmaceuticals (KALV)

View all positions for DAFNA Capital Management

Top funds holding Stoke Therapeutics

Skorpios Trust
Redmile Group
Morgan Stanley
BlackRock
Lynx1 Capital Management
Baker Bros. Advisors
Cowen And Company
Vanguard Group
Goldman Sachs Group
Franklin Resources
Geode Capital Management
Granahan Investment Management
Cormorant Asset Management
Deutsche Bank Aktiengesellschaft
FMR

View all funds holding Stoke Therapeutics